Use of gamma hardened RFID tags in pharmaceutical devices

• US 8,497,775 B2
• Filed: 11/22/2011
• Issued: 07/30/2013
• Est. Priority Date: 08/09/2006
• Status: Active Grant

• Current Assignee: EMD Millipore Corporation (Merck & Co., Inc.)
• Original Assignee: EMD Millipore Corporation (Merck & Co., Inc.)
• Inventors: Burke, Aaron
• Primary Examiner(s): Mehmood, Jennifer
• Assistant Examiner(s): MORTELL, JOHN F
• Application Number:
  US13/301,871
• Publication Number:
  US 20120061463A1
• Time in Patent Office: 616 Days
• Field of Search: 340/572.1
• US Class Current: 340/572.1
• CPC Class Codes: A61L 2/081 Gamma radiation
• CPC Class Codes: A61L 2202/24 Medical instruments, e.g. endoscopes, catheters, sharps
• CPC Class Codes: B65B 55/16 by irradiation
• CPC Class Codes: G06K 19/077 Constructional details, e.g. mounting of circuits in the carrier
• CPC Class Codes: G06K 19/07749 the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card
• CPC Class Codes: G11C 11/16 using elements in which the storage effect is based on magnetic spin effect
• CPC Class Codes: G11C 11/22 using ferroelectric elements

Abstract

A system and method for utilizing RFID tags in environments where radiation is used is disclosed. RFID tags are secured to various components of a pharmaceutical system, thereby enabling the customer to download pertinent information about the component, such as lot number, date of manufacturer, test parameters, etc. The tags can be applied to the component immediately after manufacture and can be subjected to the sterilization process without risk of data loss or corruption. The memory device within the tag utilizes a technology that does not rely upon charge storage as its mechanism to store information.

Claims

1. A pharmaceutical asset management system, comprising pharmaceutical components, each having a remotely readable and rewritable tag thereon affixed, said tag comprising a memory device employing a non-charge based storage mechanism such that the contents of such memory device are not corrupted by gamma radiation, wherein said memory device contains device specific information.

2. The pharmaceutical asset management system of claim 1, wherein said device specific information is selected from the group consisting of serial number, catalog number, date of manufacture, device specifications and device test parameters.

3. The pharmaceutical asset management system of claim 1, wherein said pharmaceutical components are selected from the group consisting of filters, bags, tubes and process instruments.

4. An automated setup and calibration procedure for pharmaceutical components, comprising:

affixing tags to said components, said tags comprising a memory device employing a non-charge based storage mechanism such that the contents of such memory device are not corrupted by gamma radiation;

storing device specific information in each of said tags;

exposing said components to gamma radiation to sterilize said components;

after said exposing step, using a reader to determine said device specific information associated with each component;

performing a calibration procedure based on said read device specific information.

5. The automated setup and calibration procedure of claim 4, wherein said device specific information is selected from the group consisting of serial number, date of manufacture, calibration values, upper and lower limits, units of measure and the data exchange protocol.

6. The automated setup and calibration procedure of claim 4, further comprising transferring said read device specific information to an automated integrity tester.

7. A method of creating a pharmaceutical asset management system, comprising a plurality of pharmaceutical components, comprising:

attaching a remotely readable and rewritable tag comprising a memory device employing a non-charge based storage mechanism, wherein the contents of said memory device are not corrupted by gamma radiation, to each of said pharmaceutical components;

writing device specific information to said memory device; and

subjecting each of said pharmaceutical components and said memory device affixed thereto to gamma radiation.

8. The method of claim 7, wherein said device specific information is selected from the group consisting of serial number, catalog number, date of manufacture, device specifications and device test parameters.

9. The method of claim 7, wherein said pharmaceutical components are selected from the group consisting of filters, bags, tubes and process instruments.

10. The method of claim 7, further comprising reading said device specific information from said memory device after said gamma radiation.